Topic: Can Biomarker Staging of Alzheimer’s Disease Help in Better Clinical Trial Design?
Speaker: Cherian Verghese, MD, Medical Director and Principal Investigator, Keystone Clinical Studies, LLC, Assistant Professor, Department of Psychiatry and Behavioral Health, Temple University School of Medicine
 
Presentation Objectives
At the end of this presentation, the participants should be able to:
1.  Describe the clinical features, prevalence and national cost of Alzheimer’s Disease;
2.  Explain the basic pathological processes in Alzheimer’s Disease;
3.  Identify the reason why medications so far do not help to alter disease progression;
4.  Review the reasons for the failure of recent clinical trials in the light of brain imaging and disease progression models;
5.  Recognize the role of early detection and intervention in the Mild Cognitive Impairment phase.